FMP
NASDAQ
1.58 USD
-0.01 (-0.633%)
Mr. Adrian G. Rawcliffe
Healthcare
Biotechnology
https://www.adaptimmune.com
NASDAQ
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sar...
0001621227
US00653A1079
00653A107
60 Jubilee Avenue
44 12 3543 0000
GB
449
May 6, 2015
0001621227
NASDAQ
Biotechnology
Healthcare
00653A107
US00653A1079
GB
1.58
2.39
1.89M
345.3M
-
0.42-2.05
-0
-
-
-
-
-2.93
-
https://www.adaptimmune.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.